Kymera Therapeutics, Inc. KYMR
131.73 USD +3.61 (+2.82%)
At closeNov 6, 2026, 5:51 PM EST
130.00 -1.73 -1.31%
After hours · Nov 6, 5:51 PM ET
126.65 Day range 132.68
58.66 52-week range 136.25
- YTD
- +69.30%
- 1 year
- +115.95%
Financial health
Altman Z-Score
43.15 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -21.1×
FY 2018 5y median -13.5× FY 2025
P/S 168×
FY 2018 5y median 41.8× FY 2025
P/B 4.2×
FY 2018 5y median 3.8× FY 2025
P/FCF -28.0×
FY 2018 5y median -14.6× FY 2025
EV/EBITDA -20.8×
FY 2018 5y median -13.8× FY 2025
EV/Sales 161×
FY 2018 5y median 41.4× FY 2025
FCF Yield -3.6%
FY 2018 5y median -6.9% FY 2025
Profitability
Gross Margin 100.0%
FY 2018 5y median 100.0% FY 2025
Operating Margin -891.3%
FY 2018 5y median -344.4% FY 2025
Net Margin -794.4%
FY 2018 5y median -330.6% FY 2025
ROE -19.7%
FY 2018 5y median -26.8% FY 2025
ROIC -20.9%
FY 2018 5y median -28.3% FY 2025
ROA -17.9%
FY 2018 5y median -22.9% FY 2025
Growth (YoY)
Revenue -16.7%
FY 2018 FY 2025
Operating Income -33.5%
FY 2018 FY 2025
EPS (diluted) -23.8%
FY 2018 FY 2025
Free Cash Flow -13.0%
FY 2018 FY 2025
Financial Health
Current Ratio 10.5×
FY 2018 5y median 5.9× FY 2025
Quick Ratio 10.5×
FY 2018 5y median 5.9× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.9×
FY 2018 5y median 0.3× FY 2025
Interest Coverage -1403×
FY 2018 5y median -916× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
